No Data
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Express News | Marinus Pharmaceuticals Inc - on Dec 6, Receives Nasdaq Notice for Minimum Bid Price Deficiency
US$1.86: That's What Analysts Think Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Is Worth After Its Latest Results
Marinus Pharmaceuticals Price Target Maintained With a $2.00/Share by HC Wainwright & Co.
D. Boral Capital Maintains Buy on Marinus Pharma, Maintains $3 Price Target
JMP Securities Maintains Marinus Pharmaceuticals(MRNS.US) With Hold Rating